

DR. MED. MARCO SIANO



Hebelstrasse 3
CH-9000 St. Gallen
Phone +41 76 324 64 46
marco.siano@kssg.ch
marco.siano@yahoo.com

Bürgerort **Berneck, St. Gallen**

Nationality **Switzerland**

Born March 18th 1974
Altstätten, St. Gallen
Three boys (8 years, 2 years, 8 months)

EDUCATION

1981-1987	Primary school in Berneck, (St. Gallen)
1987-1990	Secondary school in Heerbrugg (St. Gallen), Fast track class
1990-1994	High school, Matura Typ. C in Heerbrugg (St. Gallen)
1994-2001	University of Zurich, Medical degree
2005	Doctorate, University of Zurich (Prof. Dr. med. Pius Wyss)
2007	Board certification in Internal Medicine (FMH Diploma)
2009	Board certification in Medical Oncology (FMH Diploma)

Curriculum Vitae

MEDICAL EDUCATION

since Jan 2013	Senior Consultant/Staff Medical Oncology (Oberarzt mbF) Cantonal Hospital St. Gallen (Prof. Dr. T. Cerny)
Jan.-Aug. 2015	Clinical Researcher, Fondazione IRCCS Istituto Nazionale dei Tumori (NCI, Milano), Italy Dept. Head & Neck, Thyroid Cancers (Prof. Dr. L. Licitra)
2009-2012	Consultant Medical Oncology (Oberarzt) Cantonal Hospital St. Gallen (Prof. Dr. T. Cerny)
2007-2008	Resident in Medical Oncology, Outpatient Dept. IOSI Ospedale San Giovanni Bellinzona (Prof. Dr. F. Cavalli / Prof. Dr. M. Ghielmini)
April 2005-2006	Resident in Medical Oncology Cantonal Hospital St. Gallen (Prof. Dr. T. Cerny)
	Resident in Internal medicine Cantonal Hospital St. Gallen (Prof. Dr. P. Greminger)
April 2003-2005	Resident in Internal Medicine Cantonal Hospital Frauenfeld (Prof Dr. B. Frauchiger)
Jan.-April 2003	Postgraduate Doctorate University of Zurich (Prof Dr. P. Wyss)
2001	Resident in Surgery Kantonal Hospital Flawil (Dr. H. Itin)
1999-2000	Clerkships Psychiatry, Psychiatric Klinik (Wil, St. Gallen) Pediatric surgery, Children Hospital Zurich Forensic medicine, Institute for Rechtsmedizin (Zurich) Gynecology and Obstetrics, Universitätsspital Zurich Anesthesiology, Kantonal Hospital St. Gallen Internal medicine, Kantonal Hospital Altstätten (St. Gallen)

FURTHER MEDICAL EDUCATION

2009	Special course Palliative Medicine for Oncologists
2007/2008	Member of the 'Commission of Nutrition' (EOC, Ticino)
2009/2010	GCP Trainings, Cantonal Hospital St. Gallen 2009 / 2010
2011	Investigator Training, SAKK Bern 2011
2012	Masterclass IGR (Institut Gustave Roussy) Thyroid Cancer
2015	Clinical Researcher, Head and Neck Cancer, INT Milan

MEDICAL EXPERTISE

Disease Leader for Head and Neck cancer and Thyroid Cancer since 2009

Disease Leader for Skin cancers and Melanoma since 2012

Co-Responsible for Lung and thoracic cancers since 2009 – 2015

President of the Head and Neck Cancer Working Group of the SAKK since 2016

Broad knowledge and experience in the treatment of all solid cancers

Broad knowledge and experience in application of novel immunotherapeutic / checkpoint inhibitor and antibody treatments

Knowledge and experience in the treatment of haematological cancers

Board certification examiner for medical oncology since 2014 (FMH)

Responsible for Informatics, eHealth and chemotherapy prescription

Consultant and responsible for outpatient ward Hospital Flawil, St. Gallen

Reviewer for

'Journal for Immunotherapy of Cancer' (ISSN: 2051-1426)

'Oral Oncology' (ISSN: 1368-8375)

'Advances in Pharmacology and Pharmacy' (ISSN 2332-0044)

'Framingham Melanoma' since 2014

MANAGEMENT SKILLS

2009	Leadership course for Staff Physicians
2010	Project Management course, Cantonal Hospital St. Gallen
2013	Management course for Staff, Hochschule Luzern
2007/2008	Project Leader. IT-Tumorboard Module IOSI Bellinzona
2011/2012	Project Leader. Chemotherapy Prescription pre-study
since 2013	Project Leader. CHEMO, Implementation prescription tool
since 2009	Responsible for Inter- and Intranet oncology and IT Oncology clinic St. Gallen

RESEARCH ACTIVITIES (most important)

Principle Investigator	<p>ARCHER. A Randomized Double Blind Phase 3 of Dacomitinib Versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer (20 Patients), 1.2 Mio CHF</p> <p>CheckMate. A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Versus Ipilimumab Monotherapy in Previously Untreated Unresectable or Metastatic Melanoma, 70'000 CHF</p> <p>PAN-01. Phase II study to investigate the efficacy of panitumumab in platinum-resistant advanced head and neck squamous cancer, 44'000 CHF</p> <p>PAN-01 substudy. Validation of a gene expression profile for response on pts treated within a phase II clinical trial with advanced HNSCC. 12'000 CHF</p> <p>GCRRegistry. Upper Gastrointestinal Cancer metastasized to the brain - Analysis of pathological and clinical data</p> <p>Database. Datensatzerstellung zum Krankheitsverlauf von Head and Neck Cancer-Patienten, welche im Kanton St. Gallen behandelt wurden</p>
Subinvestigator	<p>SAKK (17/04, 16/08, 16/00, 19/09, 75/08) among many others</p>
Expertise	<p>Clinical research in Oncology Squamous cell cancers Monoclonal antibodies (anti-EGFR1, Her2, CD20)</p>

MEMBERSHIPS

International

ESMO (European Society of Medical Oncology)
ASCO (American Society of Clinical Oncology)
EHNS (European Head and Neck Society)
IASLC (International Association for the Study of Lung Cancer)
EORTC (European Organisation for Research and Treatment of Cancer)
ESO (European School of Oncology)
within ESO department coordinator for interactive online education sessions (e-sessions)
discussant in many e-grandround and oncoreviews sessions

National

SGMO (Schweizerische Gesellschaft für Medizinische Onkologie), former
SAKK (Schweizerische Arbeitsgruppe für Klinische Krebsforschung)
FMH (Foederatio Medicorum Helveticorum)
VSAO (Vereinigung Schweizer Assistenz- und Oberärzte)
within SAKK, president of the Head and Neck Working Group

LANGUAGES

German	perfect
Italian	perfect
English	perfect
French	very good

PUBLICATIONS and ABSTRACTS peer reviewed

Dummer R, **Siano M**, Hunger RE, Lindenblatt N, Braun R et al. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. *Swiss Med Wkly*. 2016;146:w14279.

Impact factor 1.895

Bossi P, Bergamini C, **Siano M**, et al. De Cecco L, Perrone F et al. Functional genomics uncover the biology behind the responsiveness of head and neck squamous cell cancer patients to cetuximab. *Clin Cancer Res*. 2016;22(15):3961-70.

Impact factor 8.193

Diem S, Keller F, Ruesch R, Maillard SA, Speiser DE, Dummer R, **Siano M**, Urner-Bloch U, Goldinger SU, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma immunotherapy? *J Immunther*. 2016;39(9):379-82.

Impact factor 3.712

Litschel R, Cogliatti S, **Siano M**. Nasolacrimal duct obstruction caused by lymphoproliferative infiltration in the course of chronic lymphocytic leukemia. *Allergy Rhinol (Providence)*. 2015 Jan;6(3):191-4.

Feilchenfeldt JW, Varga Z, **Siano M** et al. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). *Br J Cancer*. 2015;113(5):716-21.

Impact factor 7.040

Uster A, Rühlin M, Rüfenacht U, Pless M, **Siano M**, Imoberdorf R, Ballmer P. Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: A randomized controlled trial. *Nutrition*. 2013;29:1342-9.

Impact factor 3.046

Siano M, Früh M. Systemic Therapy of Neuroendocrine Tumours of the Lung. *Lung Cancer Management*. 2012;1:1-8.

Früh M, Cathomas R, **Siano M** et al. Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08). *Clin Lung Cancer*. 2012;14:34-9.

Impact factor 3.220

Siano M, Lerch E, Negretti L et al. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. *Clin Cancer Res*. 2008;14:7935-39.

Impact factor 8.193

Siano M, Infante G, Miceli R, Resteghini C, Locati L, Licitra L, Bossi P. Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting. *Ann of Oncol*. 2016 27(suppl 6):vi343.

Impact factor 9.269

Siano M, Jarisch NS, Jörger M. Presence of percutaneous endoscopic gastrostomy tube (PEG) is an independent negative prognostic factor in recurrent/metastatic head and neck squamous cell cancer (r/ mHNSCC) patients. *Ann of Oncol*. 2016 27(suppl 6):vi345.

Impact factor 9.269

Cau MC, Alfieri S, Lo Vullo S, Bergamini C, Bossi P, Resteghini C, Imbimbo M, **Siano M**, Granata R, Licitra L, Locati L. Site of metastatic disease influences adenoid cystic cancer (ACC) patients' outcome. *Ann of Oncol.* 2015 26(suppl 6):vi67–vi72. **Impact factor 9.269**

Siano M, Resteghini C, Cau MC et al. Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): a retrospective analysis. *Eur J Cancer.* 2015;51(suppl 3);S578. abstract 2865. **Impact factor 5.624**

Siano M, Molinari F, Martin V et al. Prospective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC). *Eur J Cancer.* 2015;51(suppl 3);S576. abstract 2861. **Impact factor 5.624**

Siano M, Molinari F, Martin V et al. Phase II explorative trial to prospectively investigate predictive molecular biomarkers for efficacy of panitumumab (P) in platinum-pretreated head and neck squamous cell cancer (HNSCC). *Eur J Cancer.* 2015;51(suppl 3);S560. abstract 2807. **Impact factor 5.624**

Siano M, Desax MC, Früh M, Jörger M. Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre. *Oncol Res Treat.* 2015;38(suppl 5):186. abstract V612.

Siano M, Desax MC, Früh M, Jörger M. Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB). *Oncol Res Treat.* 2015;38(suppl 5):186. abstract V614.

Siano M, Espeli V, Desax MC et al. Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival. *J Clin Oncol.* 2015;33 (suppl; abstract e17046). **Impact factor 17.96**

Schmid S, **Siano M** et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. *Lung Cancer.* 2015 Jan;87(1):85-7. Epub 2014 Nov 18. **Impact factor 3.737**

Bossi P, De Cecco L, Perrone F, Cortelazzi B, Cossu Rocca M, **Siano M**, Licitra L. Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy. *J Clin Oncol.* 2013;31 (suppl; abstr 6027). **Impact factor 17.96**

Hilbe W, Abacioglu U, Aebersold DM, Bachouchi M, Brodowicz T, Gaafar R, Holzer G, Mohn-Staudner A, Kalev D, Kalinka-Warzocho E, Kovac V, **Siano M**, Yumuk F, Tamasi L. CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. *Memo.* 2013;6:75-82.

CONGRESS posters, oral presentations

Siano M, Infante G, Miceli R, Resteghini C, Locati L, Licitra L, Bossi P. Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting. *Ann of Oncol.* 2016 27(suppl 6):vi343. **Poster**

Curriculum Vitae

Siano M, Jarisch NS, Jörger M. Presence of percutaneous endoscopic gastrostomy tube (PEG) is an independent negative prognostic factor in recurrent/metastatic head and neck squamous cell cancer (r/ mHNSCC) patients. Ann of Oncol. 2016 27(suppl 6):vi345. **Poster**

Siano M. Thyroid cancers: which molecular markers are relevant? Oncol Res Treat 2015;38(suppl 5):42 (abstract V154). **Oral**

Siano M, Molinari F, Martin V et al. Prospective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC). Eur J Cancer 2015;51(suppl 3);S576. abstract 2861. **Poster and Oral**

Siano M, Molinari F, Martin V et al. Phase II explorative trial to prospectively investigate predictive molecular biomarkers for efficacy of panitumumab (P) in platinum-pretreated head and neck squamous cell cancer (HNSCC). Eur J Cancer 2015;51(suppl 3);S560. abstract 2807. **Poster and Oral**

Siano M, Resteghini C, Cau MC et al. Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): a retrospective analysis. Eur J Cancer 2015;51(suppl 3);S578. abstract 2865. **Poster**

Siano M, Desax MC, Früh M, Jörger M. Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre. Oncol Res Treat 2015;38(suppl 5):186. abstract V612. **Oral**

Siano M, Desax MC, Früh M, Jörger M. Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB). Oncol Res Treat 2015;38(suppl 5):186. abstract V614. **Oral**

Feilchenfeldt J, Varga Z, Schuknecht B, **Siano M** et al. Gastric cancer and CNS involvement registry. EJC 2014;50(suppl 4):S10. **Poster**

Krull I, Rogowski-Lehmann N, Sigrist S, **Siano M**, Brändle M, Bilz S. Thyroid Dysfunction in a Patient Treated with Ipilimumab: Autoimmune Thyroid Disease Associated with Anti-CTLA-4 Therapy. ICE/ENDO 2014. abstract SAT-0494. **Poster**

Bossi P, De Cecco L, Perrone F, Cortelazzi B, Cossu Rocca M, **Siano M**, Licitra L. Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy. J Clin Oncol 31, 2013 (suppl; abstr 6027). **Oral**

Uster A, Rühlin M, Rufenacht U, Pless M, **Siano M**, Imoberdorf R, Ballmer PE. Individuelle Ernährungsberatung bewirkt eine signifikante Steigerung der Energie- und Eiweisszufuhr bei unterernährten, ambulanten Krebspatienten: Eine kontrollierte, randomisierte Studie. Aktuel Ernährungsmed 2012;37. P4_7 **Poster**

Siano M, Lerch E, Zucca E et al. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Blood 2007 (ASH Annual Meeting 2007, abstr. 3411) **Poster**

DISSERTATION

Siano M, Wyss P. Vaginal sacrospinous ligament fixation - a minimal invasive procedure? Medizinische Fakultät Universität Zürich. Dissertation 2005.

LECTURES (most important)

Thyroid cancers: which molecular marker are relevant? DGHO 2015

Orphan malignancies Seminar 10. Sept 2015: Neue systemische Therapiemöglichkeiten beim metastasierten Schilddrüsenkarzinom.

Siano M. Schilddrüsenkarzinome: Welche molekularen Marker sind relevant? DGHO 2015

SGV – Schweizerische Gesellschaft der Vertrauensärzte / WIN – What is new?, Fribourg, Sept 2014: Melanom – Update.

INCTR Congress 2011, Brussels, April 4-6, 2011: E-Learning.

Schweizerische Gesellschaft für Onkologie und Collegium Helveticum / Auf der Suche nach Lebensqualität in der Onkologie, Zurich, March 26, 2010: Kaleidoskop der Krebsbehandlungen.

Onko-Lunches (interne Weiterbildungen): Chur, Zürich Triemli, Luzern, Bellinzona.

ARTICLES non peer reviewed

Siano M. Das Schilddrüsenkarzinom: Inzidenz, Pathologie/molekulare Grundlagen, systemische Therapie. Schweizer Zeitschrift für Onkologie. 2017;1:xx-xx. (to be published)

Siano M. Schilddrüsenkarzinom – News-ASCO und Integration in den klinischen Alltag. Leading Opinions Hämatologie & Onkologie. 2015;4:20-23.

Zürcher-H. U, Siano M, Blum D. Antiemese und Tumormedikation. info@onkologie. 2015;1;4:20-26.

Volck AC, Siano M, Töpfer M, Abée CE, Broglie MA, Stöckli SJ. Das Adenoidzystische-Karzinom. info@onkologie. 2015;1;10-12.

Zürcher-Härdi U, Siano M, Broglie Däppen MA et al. Knochenmarksversagen bei Tumorinfiltration bei einem Patienten mit Ästhesioneuroblastom, Mantelzell-Non-Hodgkin-Lymphom und Rektumkarzinom. Schweiz. Krebs Bulletin. 2015;1;98-101.

Böhler N, Siano M, Anliker MD. Phototoxische Medikamente: Wichtigkeit der Patienteninformation. Schweiz Med Forum 2014;14(7):132-4.

Siano M. Medulläres Schilddrüsenkarzinom – Eine eigene Entität. info@onkologie 2013;4:37-39.

Hochstrasser A, Hundsberger T, Siano M. Secondary spinal anaplastic ependymoma ten years after treatment of Hodgkin's disease. Schweiz. Krebs Bulletin. 2013;2:175-8.

Siano M. Kopf-Hals-Tumoren und News zum Melanom – ESMO Kongress. Leading Opinions Hämatologie & Onkologie. 2012;5:24-26.

Siano M. Die Therapie beim NSCLC in kurativer Absicht : Aktuelle Modalitäten in allen Krankheitsstadien: eine Übersicht. Schweizer Zeitschrift für Onkologie. 2012;1:17-22.

Früh M, Siano M. Neue prädiktive Faktoren beim Nichtkleinzelligen Bronchialkarzinom. info@onkologie. 2011;1:8-10.

Siano M, Saletti P. Adenocarcinoma pancreatico: Il marcatore CA 19-9 predice la risposta al trattamento chemoterapeutico? Tribuna medica ticinese. 2008;73:350.

Curriculum Vitae

Soldini D, Siano M, Mora O et al. Wirksamkeit von Alemtuzumab und Gemcitabine in einer Patientin mit enteropathischem T-Zell Lymphom. Schweiz. Krebs Bulletin. 2007;4:346-348